Hemodialysis Concentrates
Dove Medical Supplies
FDA Clearance Information
The hemodialysis concentrates by Dove Medical Supplies were cleared via the FDA 510(k) pathway on December 22, 1988. They are classified as Class 2 devices under product code KPO.
What It Is
FDA-Cleared Indications
- Use as dialysate concentrates in hemodialysis.
- Use with a compatible hemodialysis system and appropriately treated dialysis water.
- Use to support removal of metabolic waste products and management of electrolytes during dialysis treatment.
Clinical Applications
- Routine maintenance hemodialysis for patients with kidney failure.
- Dialysis treatment for patients with chronic kidney disease who require renal replacement therapy.
- Preparation of dialysate by mixing the concentrate with treated water in a compatible dialysis machine.
- Electrolyte and acid-base management during hemodialysis under prescribed treatment settings.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The concentrate must be compatible with the dialysis machine, proportioning system, prescribed dialysate formulation, and treated water quality.
- Acid and bicarbonate concentrates may be supplied separately or in formulations intended for a specific mixing system; they are not interchangeable without confirming compatibility.
- Use requires trained dialysis personnel, correct dilution, and verification of conductivity, pH, electrolyte composition, and water quality according to facility protocol.
- The product is not implanted and has no MRI-specific device safety concern; MRI considerations relate to the dialysis equipment, access, and the patient's clinical condition.
- Incorrect concentration, contamination, or improper storage can cause serious electrolyte or acid-base abnormalities.
Frequently Asked Questions
What are the clinical indications for hemodialysis concentrates?
Hemodialysis concentrates are indicated for use in patients undergoing hemodialysis to manage electrolyte balance and remove waste products from the blood.
What outcomes have been reported in clinical studies?
Studies report effective maintenance of dialysis water quality and reduced side effects with alternative buffering agents.
What complications have been reported?
Safety data indicate potential microbial contamination and hyperacetatemia in acetate-sensitive patients.